Organised by the FIP Hospital Pharmacy Section and the FIP Board of Pharmaceutical Sciences
Biologic pharmaceuticals are very targeted medications that have made a major contribution to the clinical outcomes of patients with challenging diseases and conditions. These pharmaceuticals are very expensive and competition from products that are biologically similar has the potential of increasing patient access at a lower cost. The complexity of the science and practice of using these medications makes pharmacists’ education of these agents critical to their appropriate use. This pre-congress satellite will address these areas with active learning opportunities for the audience.
This activity is supported by Amgen
08:30 – 09:00 Introduction by the chairs
The science of biosimilars
10:20 – 10:40 Coffee/tea break (Hall 1)
12:00 – 12:30 Morning panel
12:30 – 13:40 Lunch break
The regulation of biosimilars
Education of pharmacy students and practitioners
6. 14:45 – 15:50 Overcoming the gap between clinical use of biosimilars and education of pharmacists and other healthcare providers
Arnold Vulto (Erasmus University, The Netherlands)
15:50 – 16:10 Coffee/tea break (Hall 1)
7. 16:10 – 16:30 Panel – Addressing addition to regulatory issues/clinical use and education
8. 16:30 – 17:30 Workshop
a.) What are the structural and bioequivalence issues related to biosimilars?
b.) How does the approval and naming process effect the eventual marketing and use of biosimilars?
c.) What strategies have been used to overcome barriers to adding biosimilars to hospital and clinic medication formularies?
d.) How are colleges and schools of pharmacy educating pharmacists about biosimilars both for students and as continuing professional competence for practitioners?
Please register for the Biosimilars workshop here:
For more information about the Biosimilars Workshop fees click here.